Last reviewed · How we verify
Anti-BCMA CAR T cells
At a glance
| Generic name | Anti-BCMA CAR T cells |
|---|---|
| Sponsor | Allife Medical Science and Technology Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma (PHASE1, PHASE2)
- Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT (PHASE1, PHASE2)
- A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (PHASE2)
- P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (PHASE1)
- CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma (PHASE1)
- Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma (PHASE2)
- An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (PHASE2)
- A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-BCMA CAR T cells CI brief — competitive landscape report
- Anti-BCMA CAR T cells updates RSS · CI watch RSS
- Allife Medical Science and Technology Co., Ltd. portfolio CI